Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

LUMYKRAS 240 MG COMPRIMIDOS RECUBIERTOS CON PELICULA - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/LUMYKRAS 240 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

Approved

STANDARD

LUMYKRAS 240 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

Amgen Europe B.V.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: May 23, 2024
Approval ID: 8d4c6b43c83db18f
Company: Amgen Europe B.V.
Type: Standard

Approval Details

Approval Id: 8d4c6b43c83db18f
Drug Cima Aemps Name: LUMYKRAS 240 MG COMPRIMIDOS RECUBIERTOS CON PELICULA
Register Number: 1211603004
Holder Company Name: Amgen Europe B.V.
Marketing Company Name: Amgen S.A.
Holder Company Detail Path: /organization/amgen-europe-b-v
Marketing Company Detail Path: /organization/amgen-sa
Authorization Date: 2024-05-23
Dosage Form: COMPRIMIDO RECUBIERTO CON PELÍCULA
Dose: 240 mg
Route Of Administration: VÍA ORAL
Prescription Type: Diagnóstico Hospitalario
Commercialized: Yes
Company Name: Amgen Europe B.V.
Company Detail Path: /organization/amgen-europe-b-v

Company Information

Pharmaceutical Company Name: AMGEN EUROPE B.V.
Country Name: Israel
City Name: tel aviv-jaffa,central district,country_il
Address: Simtat Maoz

Active Ingredients

SOTORASIB

240 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

May 23, 2024

Approval ID

8d4c6b43c83db18f

Type

Standard

Back to CIMA-AEMPS Approvals